Your Immunology CRO Partner

ARG Has Extensive Experience To Operationalize Clinical Research

Challenges in Immunology Clinical Trials:

  • Does your Contract Research Organization have 15+ years of therapeutic area experience?
  • Does your team know the investigators and site staff in the tight-knot immunological space?
  • Does your CRO know what to do with an unclear roadmap in a rare orphan disease?
  • Do you need specific experience, such as phase I or medical device?
  • Has your research experienced issues in patient recruitment and compliance?
  • Do you expect a wide range of global clinical trial service capabilities ?

ARG Has The Relationships And Experience To Empower Your Clinical Trial

ARG has strong relationships with leading investigators and coordinators in multiple strategic areas in immunology. Equally as important, our deep expertise, which is rooted in long-tenured project management and clinical operations team members, provides stability when asking questions and solving problems.

ARG has consistently demonstrated the capacity to operate successfully in worldwide clinical trials. Our calm experience allows us to focus on strengthening relationships, gathering facts and opinions, and building trial team solidarity in studies.

“Lessons learned over the years have allowed us to create efficiencies in patient recruitment, protocol design and eCRF database construction.”

“With 15 years in the space, ARG has gathered invaluable experience. We have built strong relationships with the KOLs and PIs conducting these immunological studies. All of this leads to better data. ARG has created a ‘deep bench’ of CRAs & Project Managers trained and experienced in immunology. Additionally, our size allows us to be flexible and nimble when working toward deliverables. All of these attributes make ARG the clear choice for your project.”

Brad Whitlow, Project Manager

A Track Record Of Successful Trial Management


Including 13 rescued studies

Serving 25 countries worldwide

With time to first patient of only 15.75 days



ARG Best Practices in Immunology Trials

Focus on Patients

  • Nurtures relationships with immunological advocacy groups
  • Innovates with our “Study champion” model
  • Understands and addresses human factors

Experience Through Adaptation

  • Leverages an ever-expanding network of drug discovery relationships
  • Demonstrates the capacity to be effective when no blueprint exists
  • Adapts to unique study design and implementation circumstances

Investment In People

  • Attracts and retains the most talented people in the industry
  • Offers employees meaningful personal and professional development
  • Empowers individuals to evolve and take ownership of decisions

Case Study

Patient First Is Central To Recruitment
and Compliance

Atlantic Research Group is currently outlining its plans to utilize what it is calling a “Study Champion.” This role will add another layer of continuity to clinical trials, shifting patient responsibility from the study site to the Study Champion. Traditionally, patient care was exclusively looked after by the sites; the new model will allow a more personal approach for patients, specifically more help getting through the trial.


A specialty biopharmaceutical company targeting the plasma replacement for the treatment of hemophilia and immune deficiencies contracted with ARG to perform comprehensive CRO services for two different Phase III studies. Regulatory requirements included an audit mid-way through the process. The Sponsor faced difficulties both recruiting patients and then ensuring compliance.


Because of our relationships and experience in these immunological therapeutic areas, we able to not only meet recruitment targets but also ensure patient compliance. This was accomplished in several ways: use of specialized home health providers, daily interactions with the patients via our Study Champion, and a unique understanding of the patient experience in these disease states.

After successfully completing an audit of protocol design, conduct, monitoring, data management, and quality assurance processes, ARG won preferred provider status.

We have also found that providing this as an option has been a great recruitment tool for sites.

In terms of patient-customer service, this role will provide an unprecedented level of patient support, and build a bridge of continuity for sites and home health care nurses.

TThe Study Champion will be an expert in the systems and tasks for study participants, a one-stop-shop for patient support.

This could include working closely with advocacy, community and physician outreach to aid in patient recruitment efforts, providing travel and lodging concierge services, assisting in navigating the complex study information including logistics, dosing, and technologies, providing valuable patient feedback allowing both sites and sponsors to take corrective action sooner.

This change will ensure participants have a dedicated team member to support them during their time in clinical studies, thereby, decreasing the number of people a participant must go through in order to obtain the support that is needed. This strategy will ultimately lead to greater compliance, satisfaction, and retention.

Moving Forward

Sponsors are realizing that there is no one-size-fits-all option for operationalizing clinical trials. The right partner is the right CRO for your trial, one that is patient-centric, has the relationships within the treater communities, and the technical know how to get the job done. Equal expertise is multiple functional areas clearly demonstrates team experience, commitment, and execution.

Your trial should enjoy high visibility in your CRO’s building, and ARG’s senior leadership are deeply involved in overseeing projects. Paul Bishop, CEO, founded ARG in 2004, maintains a close relationship with the Clinical Immunology Society (CIS) and American Academy of Asthma, Allergy & Immunology (AAAAI )and has been involved in Immunology development for over 20 years.

Immunology Specializations

ARG, with global reach, specializes in serving biotech and pharmaceutical companies in Phase I and Phase II drug development projects. We also understand that immunology clinical development projects often go hand-in-hand with rare disease, central nervous system and oncology indications.

Acute Disseminated Encephalomyelitis
Alopecia Areata
Alopecia Universalis
Ankylosing Spondylitis
Antiphospholipid Syndrome
Antisynthetase Syndrome
Aplastic Anemia
Autoimmune Diseases Mentioned On Wikipedia
Autoimmune Enteropathy
Autoimmune Hemolytic Anemia
Autoimmune Inner Ear Disease
Autoimmune Oophoritis
Autoimmune Pancreatitis
Autoimmune Polyendocrine Syndrome
Balo Concentric Sclerosis
Behçet’s Disease
Bickerstaff Brainstem Encephalitis
Bruton’s Disease
Bullous Pemphigoid
Celiac Disease
Chediak-higashi Syndrome
Chronic Fatigue Syndrome
Chronic Inflammatory Polyneuropathy
Cicatricial Pemphigoid
Cogan Syndrome
Cold Agglutinin Disease
Combined Immunodeficiency Disease
Complement Deficiencies
Congenital Agammaglobulinemia
Crest Syndrome
Crohn’s Disease
Cystic Fibrosis
Digeorge Syndrome
Drug-induced Lupus Erythematosus
Eosinophilic Fasciitis
Eosinophilic Granulomatosis With Polyangiitis
Erythema Nodosum
Familiar Chronic Mucocutaneous Candidiasis
Gestational Pemphigoid
Goodpasture Syndrome
Granulomatosis With Polyangiitis
Graves’ Disease
Guillain–barré Syndrome
Hashimoto’s Syndrome
Henoch–schönlein Purpura
Hughes–stovin Syndrome
Iga Nephropathy
Igg4-related Disease
Inflammatory Bowel Disease
Ipex Syndrome
Job Syndrome
Kawasaki Disease
Lambert–eaton Myasthenic Syndrome
Leukocyte Adhesion Defects
Lichen Planus
Linear Iga Bullous Dermatosis
Lyme Disease Chronic
Meniere’s Disease
Mixed Connective Tissue Disease
Multiple Sclerosis
Myasthenia Gravis
Myelokathexis Syndrome
Neuromyelitis Optica
Opsoclonus Myoclonus Syndrome
Optic Neuritis
Ord’s Thyroiditis
Palindromic Rheumatism
Primary Biliary Cholangitis
Primary Immunodeficiency
Primary Sclerosing Cholangitis
Psoriatic Arthritis
Raynaud Syndrome
Reactive Arthritis
Relapsing Polychondritis
Rheumatoid Arthritis
Selective Deficiency Of Iga
Selective Iga Deficiency
Sjögren Syndrome
Susac’s Syndrome
Sympathetic Ophthalmia
Systemic Lupus Erythematosus
Systemic Scleroderma
Thrombotic Thrombocytopenic Purpura
Transverse Myelitis
Type 1 Diabetes
Ulcerative Colitis
Undifferentiated Connective Tissue Disease
Vogt–koyanagi–harada Disease
Wiskott-aldrich Syndrome